USPTO Examiner CHEN STACY BROWN - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18680187COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSESMay 2024May 2025Allow1100YesNo
18645942METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18645951METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18645961METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18641205COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERYApril 2024February 2025Allow1010NoNo
18438342COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTIONFebruary 2024December 2024Allow1011YesNo
18499857ADOPTIVE CELL TRANSFER AND ONCOLYTIC VIRUS COMBINATION THERAPYNovember 2023June 2025Abandon1910NoNo
18385879COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONSOctober 2023August 2024Allow1021YesNo
18462340RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USESeptember 2023October 2024Allow1300NoNo
18242025ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAMESeptember 2023March 2025Abandon1910NoNo
18339553METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODSJune 2023April 2025Abandon2201NoNo
18329441NEUTRALIZING ANTIBODY IMMUNOASSAYSJune 2023May 2025Abandon2301NoNo
18327882CORONAVIRUS VACCINEJune 2023September 2023Allow430YesNo
18142988AAV CAPSID PRODUCTION IN INSECT CELLSMay 2023April 2025Abandon2311NoNo
18308934HYPERIMMUNIZED EGG PRODUCT FOR TREATMENT OR PREVENTION OF CORONAVIRUS INFECTIONApril 2023April 2025Allow2421YesNo
18181974Separation MethodMarch 2023June 2025Allow2820NoNo
18098949SAPONIN PURIFICATIONJanuary 2023October 2024Allow2110YesNo
18085110VIRUS PURIFICATION AND FORMULATION PROCESSDecember 2022January 2025Allow2511YesNo
18052178NUCLEIC ACID VACCINES FOR CORONAVIRUSNovember 2022January 2025Abandon2710NoNo
18051819NUCLEIC ACID VACCINES FOR CORONAVIRUSNovember 2022January 2025Abandon2710NoNo
17970036COMPOSITIONS AND METHODS FOR DELIVERY OF AAVOctober 2022December 2024Allow2610NoNo
17869306HCoV IMMUNOGENIC BOOSTER COMPOSITION FOR IMPROVING IMMUNITYAGAINST SARS-COV-2 INFECTIONJuly 2022October 2024Allow2710YesNo
17857303Virus-Like Particle ConjugatesJuly 2022January 2025Allow3110NoNo
17856774MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONSJuly 2022October 2024Allow2710YesNo
17851492SAPOVIRUS VACCINESJune 2022June 2025Allow3610YesNo
17839401HUMAN CYTOMEGALOVIRUS VACCINEJune 2022October 2024Abandon2910NoNo
17837294COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCERJune 2022April 2025Allow3411YesNo
17709599COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITYMarch 2022July 2024Allow2810YesNo
17642795LASSAVIRUS VACCINESMarch 2022May 2025Allow3800NoNo
17575462USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORSJanuary 2022April 2025Allow4030YesNo
17609217INACTIVATED VIRUS COMPOSITIONS AND ZIKA VACCINE FORMULATIONSNovember 2021June 2025Abandon4410NoNo
17512246SYSTEMS AND METHODS FOR ULTRA-SPECIFIC AND ULTRA-SENSITIVE NUCLEIC ACID DETECTIONOctober 2021March 2025Allow4010YesNo
17487690MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINSSeptember 2021July 2024Allow3411NoNo
17442871IMMUNOCHROMATOGRAPHIC ASSAY METHOD, AND TEST STRIP USED IN SAID IMMUNOCHROMATOGRAPHIC ASSAY METHODSeptember 2021March 2025Abandon4210NoNo
17478537Compositions and Methods for Dengue Virus Chimeric Constructions in VaccinesSeptember 2021May 2024Allow3221YesNo
17404143Filovirus Consensus Antigens, Nucleic Acid Constructs and Vaccines Made Therefrom, and Methods of Using SameAugust 2021October 2024Allow3820YesNo
17401079Rapid Viral Diagnostic TestAugust 2021April 2025Abandon4421NoNo
17386644VIRAL VECTOR ASSAY AND VECTORJuly 2021November 2024Allow4021YesNo
17385416THERMAL INACTIVATION OF ROTAVIRUSJuly 2021March 2025Abandon4421YesNo
17372044BOVINE HERPESVIRUS TYPE 1 (BOHV-1) VECTOR AGAINST BOVINE RESPIRATORY DISEASE COMPLEXJuly 2021January 2025Allow4220NoNo
17357368VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSESJune 2021February 2025Abandon4331YesNo
17246364VIRAL SEROLOGY ASSAYSApril 2021July 2025Abandon5021NoNo
17232751NANO-SATELLITE COMPLEXESApril 2021October 2024Allow4211YesNo
17276788CORONAVIRUS VACCINEMarch 2021November 2024Allow4410YesNo
17172300COMPOSITIONS IMMUNOGENIC AGAINST SARS CORONAVIRUS 2, METHODS OF MAKING, AND USING THEREOFFebruary 2021January 2025Abandon4741NoNo
17266049RECOMBINANT BIOLOGICALLY CONTAINED FILOVIRUS VACCINEFebruary 2021January 2025Allow4740YesNo
16972077ANTIBODIES OR ANTIBODY-FRAGMENTS THEREOF TARGETING ALPHAVIRUSES, AND COMPOSITIONS AND METHODS COMPRISING SAMEDecember 2020August 2024Allow4531YesNo
17059882TARGETING P18 FOR mTOR-RELATED DISORDERSNovember 2020September 2024Allow4511YesNo
17097687METHOD FOR DETERMINING THE SENSITIVITY OF A BACTERIAL STRAIN TO A BACTERIOPHAGENovember 2020December 2024Allow4940YesNo
17047611BACTERIOPHAGE COMPOSITIONSOctober 2020February 2025Allow5231NoNo
17040455IMMUNOSUPPRESSIVE MATERIALS AND RELATED METHODSSeptember 2020August 2024Allow4711NoNo
16981197SURFACE FUNCTIONALISED MATERIALS FOR SAMPLING BIOLOGICAL MOLECULESSeptember 2020February 2025Allow5331YesNo
16976220ATTENUATED FLAVIVIRUSESAugust 2020August 2024Allow4831YesNo
16755257MAYARO VIRUS CONSENSUS ANTIGENS, DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MAYARO VIRUS, AND COMBINATIONS THEREOFApril 2020September 2024Allow5361YesNo
16172487COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLSOctober 2018January 2019Allow310NoNo
16047524RSV-SPECIFIC BINDING MOLECULEJuly 2018March 2020Allow2011YesNo
15682341METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIESAugust 2017November 2024Abandon6090YesNo
15545337ANTI-VIRAL COMPOSITIONS CONTAINING PIKFYVE INHIBITORS AND USE THEREOFJuly 2017April 2020Allow3321YesNo
156057455'-TRIPHOSPHATE OLIGORIBONUCLEOTIDESMay 2017June 2018Allow1200NoNo
15523899METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENTMay 2017April 2019Allow2411YesNo
15404662MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINSJanuary 2017April 2019Allow2721YesNo
15315687METHOD FOR RAPID GENERATION OF AN ATTENUATED RNA VIRUSDecember 2016December 2019Allow3622YesNo
15315667METHOD FOR RAPID GENERATION OF AN INFECTIOUS RNA VIRUSDecember 2016April 2019Allow2911YesNo
15204077DNA VACCINE AGAINST VIRUS OF YELLOW FEVERJuly 2016April 2018Allow2110YesNo
15032338LIVE ATTENUATED INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILTV) VACCINES AND PREPARATION THEREOFApril 2016September 2018Allow2921NoNo
15132436Pestivirus SpeciesApril 2016April 2018Allow2411YesNo
14935281COMPOSITIONS AND METHODS FOR ADMINISTRATION OF VACCINES AGAINST DENGUE VIRUSNovember 2015February 2018Allow2820YesNo
14652066COMPOSITIONS, METHODS OF ADMINISTRATION AND USES FOR TRIVALENT DENGUE VIRUS FORMULATIONSJune 2015September 2017Allow2721YesNo
14439967EFFECT OF HBV ON CLINICAL OUTCOME OF HEPATOCELLULAR CARCINOMA CANCER PATIENTSApril 2015January 2018Allow3340NoNo
14429559VIRUSES ASSOCIATED WITH IMMUNODEFICIENCY AND ENTEROPATHY AND METHODS USING SAMEMarch 2015February 2017Allow2311YesNo
14407012COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUSDecember 2014March 2017Allow2721YesNo
14400642CROSS-REACTIVE ANTIBODIES AGAINST DENGUE VIRUS AND USES THEREOFNovember 2014September 2016Allow2211YesNo
14182731NOVEL NEUTRALIZING IMMUNOGEN (NIMIV) OF RHINOVIRUS AND ITS USES FOR VACCINE APPLICATIONSFebruary 2014March 2016Allow2511YesNo
14165126T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTIONJanuary 2014April 2016Allow2611YesNo
14090221ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLSNovember 2013April 2016Allow2920NoNo
14039148RSV SPECIFIC BINDING MOLECULESeptember 2013October 2015Allow2511YesNo
14036412PESTIVIRUS SPECIESSeptember 2013January 2016Allow2821NoNo
13984702COMBINATION OF BIOMARKERS FOR THE DETECTION AND EVALUATION OF HEPATITIS FIBROSISAugust 2013December 2016Allow4031NoNo
13942064RECOMBINANT BICISTRONIC FLAVIVIRUS VECTORSJuly 2013August 2015Allow2511YesNo
13825049RECOMBINANT FLAVIVIRAL CONSTRUCTS AND USES THEREOFJune 2013May 2015Allow2620YesNo
13740100DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINESJanuary 2013May 2015Allow2830YesNo
13633436Replication-Defective Flavivirus Vaccines and Vaccine VectorsOctober 2012August 2015Allow3421YesNo
13504464DNA VACCINE AGAINST VIRUS OF YELLOW FEVERAugust 2012March 2016Allow4621YesYes
13492884COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUSJune 2012October 2014Allow2821YesNo
13406153RECOMBINANT FLAVIVIRUS VACCINESFebruary 2012June 2014Allow2821YesNo
13321460Compositions And Methods For The Therapy And Diagnosis Of InfluenzaFebruary 2012January 2014Allow2621YesNo
13357189NOVEL ANTIVIRAL PEPTIDES AGAINST INFLUENZA VIRUSJanuary 2012August 2015Allow4321NoNo
13309498MULTI PLASMIDS SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUSDecember 2011November 2012Allow1210NoNo
13274285DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINESOctober 2011January 2014Allow2750YesNo
13230209DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, NUCLEOTIDE SEQUENCE AND ANTIBODY COMPOSITIONSeptember 2011April 2014Allow3121NoNo
13130554MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2September 2011August 2014Allow3921YesNo
13130559MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2September 2011August 2014Allow3921YesNo
13199348Host cell specific binding molecules capable of neutralizing viruses and uses thereofAugust 2011August 2014Allow3510NoNo
13190547Assay for the diagnosis of flaviviral infection using antibodies with high affinity for NS1 protein of flavivirus in hexameric formJuly 2011December 2013Allow2841YesNo
13102685DENGUE CHIMERIC VIRUSESMay 2011March 2012Allow1101YesNo
12995024EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOFJanuary 2011June 2015Allow5461YesNo
12922513REPLICATION-DEFECTIVE FLAVIVIRUS VACCINES AND VACCINE VECTORSDecember 2010April 2014Allow4321NoNo
12956460FLAVIVIRUS FUSION INHIBITORSNovember 2010December 2011Allow1211YesNo
12809345EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 1A AND 1BNovember 2010June 2013Allow3611YesNo
12808565EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 6ANovember 2010June 2013Allow3611NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, STACY BROWN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
0
(0.0%)
Examiner Reversed
3
(100.0%)
Reversal Percentile
91.5%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
38
Allowed After Appeal Filing
15
(39.5%)
Not Allowed After Appeal Filing
23
(60.5%)
Filing Benefit Percentile
62.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 39.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHEN, STACY BROWN - Prosecution Strategy Guide

Executive Summary

Examiner CHEN, STACY BROWN works in Art Unit 1671 and has examined 279 patent applications in our dataset. With an allowance rate of 92.8%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner CHEN, STACY BROWN's allowance rate of 92.8% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHEN, STACY BROWN receive 2.28 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHEN, STACY BROWN is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +7.1% benefit to allowance rate for applications examined by CHEN, STACY BROWN. This interview benefit is in the 37% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 29.8% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 59.4% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 91.4% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 71.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 64.4% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 25.8% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.